Restoration of lysosomal membrane integrity in cell models of Pompe disease depends on fatty acid synthase and its product palmitic acid. [PDF]
Le Guillou E +12 more
europepmc +1 more source
Broadening applications for intrathecal gene therapy: a case for lysosomal storage diseases. [PDF]
eBioMedicine.
europepmc +1 more source
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets. [PDF]
Ziółkowska EA +5 more
europepmc +1 more source
Naturally occurring lysosomal storage disease consistent with neuronal ceroid lipofuscinosis in a group of 5 related captive rhesus macaques (<i>Macaca mulatta</i>). [PDF]
Olstad K +5 more
europepmc +1 more source
SARS-CoV-2 intra-host viral diversity associated with host innate and vaccine-induced immunity in an obese mouse model. [PDF]
Song W +15 more
europepmc +1 more source
Management Strategies for CLN2 Disease [PDF]
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by ...
Boris Zernikow +2 more
exaly +6 more sources
Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies [PDF]
Introduction : Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric neurodegenerative condition, which is usually fatal by mid-adolescence.
Igor Prpic +2 more
exaly +6 more sources

